Basilea Pharmaceutica (OTCMKTS:BPMUF) Upgraded to “Strong-Buy” by HC Wainwright

HC Wainwright upgraded shares of Basilea Pharmaceutica (OTCMKTS:BPMUF) to a strong-buy rating in a research report released on Monday, Zacks.com reports.

Basilea Pharmaceutica Price Performance

Shares of BPMUF stock opened at $51.26 on Monday. Basilea Pharmaceutica has a 1-year low of $38.60 and a 1-year high of $51.26. The company has a 50-day moving average of $49.47 and a two-hundred day moving average of $46.70.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.